Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11

Iga Kucharska†‡, Elaine Thai1,2†, Ananya Srivastava1,2, John L Rubinstein1,2,3, Régis Pomeès1,2, Jean-Philippe Julien1,2,4* 

1Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Canada; 2Department of Biochemistry, University of Toronto, Toronto, Canada; 3Department of Medical Biophysics, University of Toronto, Toronto, Canada; 4Department of Immunology, University of Toronto, Toronto, Canada

Abstract Plasmodium sporozoites express circumsporozoite protein (CSP) on their surface, an essential protein that contains central repeating motifs. Antibodies targeting this region can neutralize infection, and the partial efficacy of RTS,S/AS01 – the leading malaria vaccine against P. falciparum (Pf) – has been associated with the humoral response against the repeats. Although structural details of antibody recognition of PfCSP have recently emerged, the molecular basis of antibody-mediated inhibition of other Plasmodium species via CSP binding remains unclear. Here, we analyze the structure and molecular interactions of potent monoclonal antibody (mAb) 3D11 binding to P. berghei CSP (PbCSP) using molecular dynamics simulations, X-ray crystallography, and cryoEM. We reveal that mAb 3D11 can accommodate all subtle variances of the PbCSP repeating motifs, and, upon binding, induces structural ordering of PbCSP through homotypic interactions. Together, our findings uncover common mechanisms of antibody evolution in mammals against the CSP repeats of Plasmodium sporozoites.

Introduction

Despite extensive biomedical and public health measures, malaria persists as a major global health concern, with an estimated 405,000 deaths and 228 million cases annually (WHO, 2019). Moreover, resistant strains have been detected against all currently available antimalarial drugs, including sulfadoxine/pyrimethamine, mefloquine, halofantrine, quinine, and artemisinin (Cui et al., 2015; Ross and Fidock, 2019). Although ~94% of deaths are caused by Plasmodium falciparum (Pf) (WHO, 2019), other Plasmodium species that infect humans (P. vivax, P. malariae, P. knowlesi and P. ovale) also cause debilitating disease and have been associated with fatal outcomes (Lover et al., 2018). All Plasmodium species have a complex life cycle divided between a vertebrate host and an Anopheles mosquito vector (Hall and Fauci, 2009). During a blood meal, sporozoites are deposited into the skin of a host organism from the salivary glands of a mosquito, and subsequently migrate through the bloodstream to infect host hepatocytes (de Koning-Ward et al., 2015). Due to the small number of parasites transmitted and the expression of protein antigens that possess conserved functional regions (Rosenberg et al., 1990; Smith et al., 2014), the pre-erythrocytic sporozoite stage of the Plasmodium life cycle has long been considered a promising target for the development of an anti-malarial vaccine (Nussenzweig and Nussenzweig, 1984).

Circumsporozoite protein (CSP) is the most abundant protein on the surface of Plasmodium sporozoites, and is necessary for parasite development in mosquitoes and establishment of infection in host liver cells (Cerami et al., 1992; Frevert et al., 1993; Ménard et al., 1997). Flanked by N- and C-terminal domains, CSP contains an unusual central region consisting of multiple, short (4 to 8)
amino acid (aa) repeats (Eichinger et al., 1986; Dame et al., 1984; Plassmeyer et al., 2009; Zavala et al., 1983). The sequence of the repeating motif depends on the Plasmodium species and field isolate (Chenet et al., 2012; Rich et al., 2000; Tahar et al., 1998). Importantly, the central region of CSP is highly immunodominant and antibodies targeting the repeats can inhibit sporozoite infectivity by preventing parasite migration (Mishra et al., 2012) and attachment to hepatocytes (Potocnjak et al., 1980; Yoshida et al., 1980). PfCSP is a major component of the leading malaria vaccine RTS,S/AS01, which is currently undergoing pilot implementation in Africa (Adepoju, 2019; Draper et al., 2018). Anti-PfCSP repeat antibodies have been suggested to form the predominant humoral immune response elicited by RTS,S/AS01, and correlate with vaccine efficacy (Doban˘o et al., 2019; McCall et al., 2018; Olotu et al., 2016). However, RTS,S/AS01 offers only modest and short-lived protection (RTS,S Clinical Trials Partnership et al., 2012; RTS,S Clinical Trials Partnership et al., 2011); thus, it is critical to develop a better molecular understanding of the antibody response against this Plasmodium antigen, particularly the repeat region (Davies et al., 2015; Doolan, 2011; Illingworth et al., 2019), to obtain valuable information needed for improved vaccine design.

Our understanding of Plasmodium biology and key host-parasite interactions has been enhanced by studies using rodent parasites, including P. berghei (Pb), P. chabaudi and P. yoelii (De Niz and Heussler, 2018). In vivo studies evaluating the inhibitory potential of mAbs are often derived from these rodent parasite models, or transgenic rodent sporozoites harboring PfCSP, as Pf fails to infect rodents. For example, mAb 3D11 was isolated from mice exposed to the bites of mosquitoes that had been infected with γ-irradiated Pb parasites (Yoshida et al., 1980). mAb 3D11 recognition of the PbCSP central repeat region on the surface of live sporozoites resulted in abolished Pb infectivity in vitro and in vivo (Cochrane et al., 1976). Electron micrographs of Pb sporozoites pre-treated with mAb 3D11 revealed the presence of amorphous, precipitated material on the parasite surface characteristic of the circumsporozoite precipitation reaction (Yoshida et al., 1980). This antibody continues to be widely used in model systems of sporozoite infection. For example, a recent study used mAb 3D11 in combination with transmission-blocking mAb 4B7 to show that antibody targeting of...
Figure 1. Comparison of PfCSP and PbCSP repeat sequences and structures. (A) Schematic representations of PfCSP strain NF54 and PbCSP strain ANKA, each comprising an N-terminal domain, central repeat region, and C-terminal domain. The junctional region (J) immediately following the N-terminal domain of PfCSP is indicated. Colored bars represent each repeat motif. The sequences of each CSP central repeat region and corresponding peptides used in the study are shown below their respective schematics. (B-G) Conformational ensembles of CSP peptides in solution from molecular dynamics simulations. (B) Superposition of the conformations of the four PfCSP-derived peptides at each nanosecond. The peptides are aligned to the conformational median structure and only the backbone is shown for clarity. (C) Ensemble-averaged backbone-backbone hydrogen-bonding maps for each PfCSP peptide sequence. The propensity for hydrogen bonds between the NH groups (y-axis) and CO groups (x-axis) is indicated by the color scale on the right. (D) Sample molecular dynamics snapshots of the highest-propensity turn for each PfCSP peptide are shown as sticks with hydrogen bonds shown as gray lines. The highest-propensity turn for each peptide is indicated by the arrowhead on the corresponding Figure 1 continued on next page
hydrogen-bonding map. (E) Superposition of the conformations of the four PbCSP-derived peptides at each nanosecond. The peptides are aligned to the conformational median structure and only the backbone is shown for clarity. (F) Ensemble-averaged backbone-backbone hydrogen-bonding maps for each PbCSP peptide sequence. The propensity for hydrogen bonds between the NH groups (y-axis) and CO groups (x-axis) is indicated by the color scale on the right. (G) Sample molecular dynamics snapshots of the highest-propensity turn for each PbCSP peptide are shown as sticks with hydrogen bonds shown as gray lines. The highest-propensity turn for each peptide is indicated by the arrowhead on the corresponding hydrogen-bonding map. The online version of this article includes the following figure supplement(s) for figure 1:

**Figure supplement 1.** Ensemble-averaged hydrogen-bonding propensities for PICSP- and PbCSP-derived peptides.

**Figure supplement 2.** Experimental details of MD simulations.

both the pre-erythrocytic and sexual stages of a Pf25-transgenic Pb parasite led to a synergistic reduction of parasite transmission in mice (Sherrard-Smith et al., 2018). However, it remains unclear whether murine mAb 3D11 recognizes the central domain of PbCSP with the same molecular principles as the most potent human anti-PfCSP repeat antibodies, for which molecular details have recently emerged (Imkeller et al., 2018; Julien and Wardemann, 2019; Kisalu et al., 2018; Murugan et al., 2020; Oyen et al., 2018; Tan et al., 2018; Triller et al., 2017).

Here, we characterized the structure of the PbCSP repeats unliganded and as recognized by mAb 3D11. Our molecular studies reveal that mAb 3D11 binds across all PbCSP repeat motifs and induces structural ordering of PbCSP in a spiral-like conformation using homotypic interactions.

**Results**

**Repeat motifs of PfCSP and PbCSP have similar structural propensities**

The central repeats of PICSP and PbCSP consist of recurring 4-aa motifs rich in asparagine and proline residues (Figure 1A). PICSP is composed of repeating NANP motifs interspersed with intermittent NVDP repeats, and a singular NPDp motif in the junction immediately following the N-terminal domain. While the major repeat motif of PICSP is often referred to as NNP, numerous reports have identified NPNA as the structurally relevant unit of the central region (Kisalu et al., 2018; Oyen et al., 2017; Dyson et al., 1990; Ghasparian et al., 2006). Similarly, the central domain of PbCSP contains an array of PPPP and PAPP motifs interspersed with NPD or NAND motifs (Figure 1A). Notably, both orthologs contain the conserved pentamer, KLKQP, known as Region I, at the C-terminal end of the N-terminal domain.

To examine and compare the structural properties of the various Pf and Pb repeat motifs in solution, we performed molecular dynamics (MD) simulations using eight different peptides ranging in length from 15 to 20 aa, with four peptides derived from Pf [KQPADGNPDNPANPNP ('KQPA'); NPD NPANPNDPDNPANP ('NPDP'); (NVDPNANP)2NVDP ('NVDP'); and (NPD)2 ('NPDA')], and four peptides from Pb [(PPPNPND)2 ('NPND'); (PPPNDPND)2 ('NAND'); (PAPPNDPND)2 ('PAPP'); and PPPNPNDPAPPANAD ('Mixed'); Figure 1B–G]. Each simulation was conducted in water for a total production time of 18 µs. All eight peptides were highly disordered and adopted a large ensemble of conformations with low to moderate secondary structure propensities (Figure 1B and E), which are best described in statistical terms. The only secondary structure observed was local, and consisted of sparse, transient hydrogen-bonded turns (Figure 1C and F, Figure 1—figure supplement 1 and Figure 1—figure supplement 2, and Supplementary file 1). In particular, these interactions consisted of forward α-, β-, and γ-turns, with the β-turns being the most populated (up to 40%; Figure 1C and F), consistent with previous NMR studies focused on the NANP repeats (Dyson et al., 1990). Across all peptides, the average β-turn lifetime ranged from 2.7 ± 0.2 ns for the Pb PPNA turn to 4.4 ± 0.4 ns for DPNA turns found within PICSP (Supplementary file 1).

In line with reports identifying NPD as the main structural repeating unit of PICSP (Kisalu et al., 2018; Oyen et al., 2017; Dyson et al., 1990; Ghasparian et al., 2006), turns were predominantly observed within these motifs, as well as DPNA, NPDV, and ADGN sequences amongst the PICSP peptides. NPND and PPNA exhibited the greatest propensity to form β-turns of the PbCSP repeats. Importantly, each individual motif consistently exhibited the same structural tendencies, independent of their position and the overall peptide sequence in which they were contained (Figure 1C and F, and Supplementary file 1). Furthermore, using the probability rule stating that two events
are independent if the equation $P(A \cap B) = P(A)P(B)$ holds true, we show that the presence of an intramolecular hydrogen bond in one motif does not alter the hydrogen-bonding propensities of adjacent motifs (Figure 1—figure supplement 2B and C). Therefore, in both PICSP and PbCSP we conclude that there is no discernable cooperativity between the structures of different repeat motifs, and as such, in the absence of extended or nonlocal secondary structure, each of these motifs behaves as an independent unit with its own intrinsic secondary structure propensities.

To examine the influence of Asn, Asp, and Gln sidechains on the conformational ensemble of the peptides, we computed contact maps for backbone-sidechain hydrogen bonds (Figure 1—figure supplement 1 and Supplementary file 1). We found that the majority of contacts are in the form of pseudo $\alpha$-turns and $\beta$-turns, with backbone NH groups donating to sidechain O atoms. Notably, we discovered that these transient sidechain contacts do not have a stabilizing effect on backbone-backbone hydrogen bonds and consequently, are not correlated with the presence of these bonds (numerical example in Figure 1—figure supplement 2B and C).

In summary, the four Pf and four Pb peptides corresponding to CSP central repeats were all found to be highly disordered, resulting in an ensemble of conformations. The only secondary structure elements present were sparse and local hydrogen-bonded turns within each motif. Each structural motif acted independently from adjacent sequences and behaved similarly in various peptides.
Multiple copies of mAb 3D11 bind PbCSP with high affinity

Next, we investigated the binding of mAb 3D11 to the PbCSP repeat of low structural propensity. Our biolayer interferometry (BLI) studies indicated that 3D11 Fab binds PbCSP with complex kinetics, but overall high affinity (Figure 2A). Isothermal titration calorimetry (ITC) also indicated a high affinity interaction, with a $K_D$ value of 159 ± 47 nM (Figure 2B). In addition, ITC revealed a very high binding stoichiometry ($N = 10 ± 1$), suggesting that approximately ten copies of 3D11 Fab bound one molecule of PbCSP simultaneously. Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) characterization of the 3D11 Fab-PbCSP complex confirmed the high binding stoichiometry with a molecular weight of 587 ± 7 kDa for the complex (Figure 2C–D). This size is consistent with approximately eleven 3D11 Fabs bound to one molecule of PbCSP, and thus, is in agreement with the results from the ITC studies within experimental error. Therefore, through a number of biophysical studies, we show that up to eleven copies of 3D11 Fab can bind simultaneously to PbCSP with high affinity.
Despite binding in nearly identical conformations, differences exist in the molecular details of 3D11 Fab binding to each peptide that provide key insights into mAb 3D11 recognition of PbCSP. Our crystal structures revealed that more van der Waals contacts were formed by a Pro residue in the PPPP and NPND motifs compared to an Ala at the same position in the PAPP and NAND motifs (Figure 3D). Consequently, the epitopes of the NAND, NPND and Mixed peptides had a slightly greater buried surface area (BSA; 753, 762, and 765 Å², respectively) than the PAPP peptide (743 Å²), which only consists of Ala-containing motifs (Supplementary file 2). In particular, Pro10 of the PPPP motif found in the NAND and NPND peptides forms more van der Waals interactions with antibody residues H.Asn33 and H.Tyr52 compared to Ala10 of the PAPP motif present in PAPP and Mixed peptides. Similarly, Pro6 of the NPND motif in the NPND and Mixed peptides makes additional interactions with antibody residue K.Leu50 that are not present for Ala6 of the NAND motif within the PAPP and NAND peptides (Supplementary file 2). These differences in interactions observed at the atomic level directly relate to the binding affinities measured by ITC, where the PbCSP peptides that bury more surface area in the 3D11 paratope have the highest binding affinities (Figure 3A).

Table 1. X-ray crystallography data collection and refinement statistics.

|                  | 3D11-PAPP | 3D11-NAND | 3D11-NPND | 3D11-Mixed |
|------------------|-----------|-----------|-----------|------------|
| Beamline         | APS-23-ID-D | APS-23-ID-D | NSLS-II-17-ID-1 | APS-23-ID-B |
| Wavelength (Å)   | 1.033170 | 1.033200 | 0.979329 | 1.033167 |
| Space group      | P3221     | P3221     | P3221     | P3221     |
| a, b, c (Å)      | 59.3, 59.3, 233.5 | 59.7, 59.7, 234.9 | 59.9, 59.9, 235.0 | 60.3, 60.3, 233.7 |
| α, β, γ (°)      | 90, 90, 120 | 90, 90, 120 | 90, 90, 120 | 90, 90, 120 |
| Resolution (Å) † | 40.0–1.60 (1.70–1.60) | 40.0–1.55 (1.65–1.55) | 40.0–2.27 (2.37–2.27) | 40.0–1.55 (1.65–1.55) |
| No. molecules in ASU | 1         | 1         | 1         | 1         |
| No. observations | 1,210,903 (196,555) | 684,564 (117,091) | 450,057 (47,142) | 1,423,235 (247,601) |
| No. unique observations | 64,371 (10,497) | 70,664 (11,753) | 23,398 (2,556) | 72,981 (12,222) |
| Multiplicity     | 18.8 (18.7) | 9.5 (9.7) | 19.1 (17.4) | 19.5 (20.3) |
| Rmerge (%)       | 10.3 (84.7) | 8.4 (80.1) | 13.8 (57.1) | 8.3 (78.0) |
| Rfree (%)        | 2.4 (20.1) | 2.9 (26.5) | 3.2 (13.5) | 1.9 (17.6) |
| <I/σ I>          | 16.3 (1.5) | 13.8 (1.5) | 19.0 (4.1) | 19.6 (1.7) |
| CC1/2            | 99.9 (68.0) | 99.9 (56.7) | 99.9 (93.5) | 99.9 (84.3) |
| Completeness (%) | 99.9 (100.0) | 98.3 (97.2) | 99.3 (94.4) | 100.0 (100.0) |
| Refinement Statistics |           |           |           |           |
| Reflections used in refinement | 64,275 | 70,660 | 23,327 | 72,843 |
| Reflections used for R-free | 1999 | 1986 | 1173 | 2000 |
| Non-hydrogen atoms | 3823 | 3915 | 3665 | 3858 |
| Macromolecule    | 3411     | 3423     | 3382     | 3439     |
| Water            | 384      | 380      | 259      | 359      |
| Heteroatom       | 28       | 112      | 24       | 60       |
| Rwork/Rfree      | 15.9/18.8 | 16.4/18.4 | 16.6/22.2 | 16.6/18.1 |
| Rms deviations from ideality |           |           |           |           |
| Bond lengths (Å) | 0.016    | 0.010    | 0.006    | 0.011    |
| Bond angle (°)   | 1.43     | 1.15     | 0.87     | 1.22     |
| Ramachandran plot |           |           |           |           |
| Favored regions (%) | 98.9  | 98.0     | 97.7     | 98.2     |
| Allowed regions (%) | 1.1   | 2.0      | 2.3      | 1.8      |
| B-factors (Å²)   | Wilson B-value | 27.1 | 24.0 | 32.0 | 26.3 |
| Average B-factors | 35.0 | 31.4 | 35.2 | 31.2 |
| Average macromolecule | 33.6 | 29.4 | 34.8 | 29.7 |
| Average heteroatom | 54.4 | 54.8 | 54.4 | 57.6 |
| Average water molecule | 46.3 | 41.9 | 38.3 | 41.2 |

Kucharska, Thai, et al. eLife 2020;9:e59018. DOI: https://doi.org/10.7554/eLife.59018
mAb 3D11 is cross-reactive with subtly different PbCSP motifs in the central repeat

We next sought to define the exact mAb 3D11 epitope. We first conducted BLI studies to confirm that mAb 3D11 does not bind the PbCSP C-terminal domain (residues 202–318; Figure 3—figure supplement 1A). Next, we performed ITC studies to evaluate 3D11 Fab binding to each of the four peptides derived from the PbCSP central repeat region that were used in our MD simulations (Figure 3A). Our experiments revealed that mAb 3D11 preferentially binds the NPND and Mixed peptides with high affinity ($K_D = 45 \pm 15$ nM and $44 \pm 4$ nM, respectively), but also binds the NAND and PAPP peptides, albeit with lower affinity ($K_D = 207 \pm 1$ nM and $611 \pm 139$ nM, respectively).

To gain insight into the molecular basis of this preference, we solved the X-ray crystal structures of 3D11 Fab in complex with each peptide. The structure of the 3D11 Fab-NPND complex was determined at 2.30 Å resolution, while the structures of 3D11 Fab in complex with each of the other three peptides were all solved at ~1.60 Å resolution (Table 1). Interestingly, all four peptides adopted almost identical conformations when bound by 3D11 Fab (Figure 3B and Figure 3—figure supplement 1), fitting deep into the binding groove and forming a curved, U-shaped structure (Figure 3C). Amongst all four peptides, the mAb 3D11 core epitope consisted of eight residues [PN(A/P)NDP(A/P)P] with an all-atom RMSD <0.5 Å. Importantly, this shared recognition mode ideally positions aromatic side chains in the mAb 3D11 complementarity determining regions (CDRs) to form favorable pi-stacking and hydrophobic cage interactions around each PbCSP peptide (Figure 3—figure supplement 2). Indeed, the majority of these contacts are made with residues that are conserved between all four PbCSP repeat peptides, and thus, contribute to the cross-reactive binding profile of mAb 3D11.

Despite binding in nearly identical conformations, differences exist in the molecular details of 3D11 Fab binding to each peptide that provide key insights into mAb 3D11 recognition of PbCSP. Our crystal structures revealed that more van der Waals contacts were formed by a Pro residue in the PPPP and NPND motifs compared to an Ala at the same position in the PAPP and NAND motifs (Figure 3D). Consequently, the epitopes of the NAND, NPND and Mixed peptides had a slightly greater buried surface area (BSA; 753, 762, and 765 Å$^2$, respectively) than the PAPP peptide (743 Å$^2$), which only consists of Ala-containing motifs (Supplementary file 2). In particular, Pro10 of the PPPP motif found in the NAND and NPND peptides forms more van der Waals interactions with antibody residues H.Asn33 and H.Tyr52 compared to Ala10 of the PAPP motif present in PAPP and Mixed peptides. Similarly, Pro6 of the NPND motif in the NPND and Mixed peptides makes additional interactions with antibody residue K.Leu50 that are not present for Ala6 of the NAND motif within the PAPP and NAND peptides (Supplementary file 2). These differences in interactions observed at the atomic level directly relate to the binding affinities measured by ITC, where the PbCSP peptides that bury more surface area in the 3D11 paratope have the highest binding affinities (Figure 3A).

3D11 binding stabilizes the central PbCSP repeat in a spiral-like conformation

To understand how mAb 3D11 recognizes full-length PbCSP, we performed cryoEM analysis on the SEC-purified 3D11 Fab-PbCSP complex (Figure 2D). A dataset of 165,747 3D11 Fab-PbCSP particle images was refined with no symmetry imposed, resulting in a 3.2 Å resolution reconstruction of 3D11 Fabbs peripherally arranged around PbCSP with their variable domains clustered around a central density (Figure 4, Table 2, and Figure 4—figure supplement 1 and Figure 4—figure supplement 2). Although the low-pass filtered (20 Å) cryoEM map of the 3D11 Fab-PbCSP complex contains visible density for >10 3D11 Fabbs (Figure 4—figure supplement 2F), only the density for the seven central Fabs was strong enough to warrant building a molecular model. Indeed, 3D...
Figure 4. Spiral organization of the PbCSP repeat upon 3D11 Fab binding. (A) The cryoEM map of the 3D11 Fab-PbCSP complex reveals high-resolution information for seven predominant 3D11 Fabs. Regions corresponding to Fabs are colored from pink to gray. (B) CryoEM map of the 3D11 Fab-PbCSP complex is shown as a transparent light gray surface with the PbCSP region highlighted in black. (C) The PbCSP model built into the cryoEM map is shown in dark gray as sticks and aligned to the schematic representation of the PbCSP protein sequence.

The online version of this article includes the following video and figure supplement(s) for figure 4:

Figure supplement 1. CryoEM data processing workflow in cryoSPARC v2.
Figure supplement 2. CryoEM analysis of the 3D11 Fab-PbCSP complex.
Figure supplement 3. Comparison between the 3D11 Fab-PbCSP cryoEM structure and 3D11 Fab-NPND peptide crystal structure.
Figure 4—video 1. 3D Variability Analysis on 165,747 particle images of the 3D11 Fab-PbCSP complex.

https://elifesciences.org/articles/59018#fig4video1
Variability Analysis \cite{Punjani2020} in cryoSPARC v2 \cite{Punjani2017} revealed continuous flexibility at the N- and C-termini of the 3D11 Fab-PbCSP complex (Figure 4—video 1). The PbCSP repeat forms the core of the complex and is arranged into a triangular spiral of 51 Å pitch and 16 Å diameter (Figure 4B–C), which fits 61 of the 108 residues in the PbCSP central region. We assigned the density to the high-affinity PPPPNPND repeats.

The angle between two Fab variable domains is \( \approx 126^\circ \), such that approximately three Fabs are required to complete one full turn of the spiral (Figure 4A). The cryoEM structure of the 3D11 Fab-PbCSP complex and the crystal structures of the 3D11 Fab-peptide complexes are in remarkable agreement for both the Fab (backbone RMSD = 0.69 Å) and the PbCSP repeat region (backbone RMSD = 0.66 Å; Figure 4—figure supplement 3). Minor differences exist in the N- and C-termini of the peptides, presumably because the termini are largely unrestricted in the crystal structures compared to the cryoEM structure.

**Contacts between 3D11 Fabs stabilize the PbCSP spiral structure**

To access their repeating and densely-packed epitopes, 3D11 Fabs are closely arranged against one another in the 3D11 Fab-PbCSP complex. Indeed, the epitope for a single Fab can be defined by 14 residues (PPPPNPNDPPPPNP, Supplementary file 3), with the six C-terminal residues constituting the beginning of the epitope for the adjacent Fab. When considering two adjacent Fabs as a single binding unit, the BSA of the Fabs is 1313 Å\(^2\), and 1636 Å\(^2\) for PbCSP. Interestingly, we observe

| Table 2. CryoEM data collection and refinement statistics. |
|-----------------------------------------------------------|
| **Data collection**                                       |
| Electron microscope                                       | Titan Krios G3 |
| Camera                                                    | Falcon 3EC    |
| Voltage (kV)                                              | 300           |
| Nominal magnification                                     | 75,000        |
| Calibrated physical pixel size (Å)                        | 1.06          |
| Total exposure (e- /Å\(^2\))                             | 42.7          |
| Number of frames                                          | 30            |
| **Image processing**                                      |
| Motion correction software                                | cryoSPARCv2   |
| CTF estimation software                                    | cryoSPARCv2   |
| Particle selection software                               | cryoSPARCv2   |
| 3D map classification and refinement software             | cryoSPARCv2   |
| Micrographs used                                          | 2080          |
| Particles selected                                        | 669,223       |
| Global resolution (Å)                                     | 3.2           |
| Particles contributing to final map                       | 165,747       |
| **Model building**                                        |
| Modeling software                                         | Coot, phenix.real_space_refine |
| Number of residues built                                  | 3085          |
| RMS (bonds)                                               | 0.002         |
| RMS (angles)                                              | 0.56          |
| Ramachandran favored (%)                                  | 95.8          |
| Rotamer outliers (%)                                      | 0.5           |
| Clashscore                                                | 6.27          |
| MolProbity score                                          | 1.63          |
| EMRinger score                                            | 2.54          |

Kucharska, Thai, et al. eLife 2020;9:e59018. DOI: https://doi.org/10.7554/eLife.59018
Figure 5. Homotypic interactions between 3D11 Fabs stabilize the 3D11 Fab-PbCSP complex. (A and B) Close-up views of adjacent 3D11 Fabs from the cryoEM structure in complex with PbCSP (black). 3D11 Fabs bound to PbCSP form homotypic contacts with each adjacent Fab through two interfaces; one consisting of CDRs from the heavy and light chains of Fabs A and B (interface 1, A), and the second mediated by residues in FR3 of Fab A HC and FR3 of Fab C LC (interface 2, B). Variable domains of Fabs are shown in white. HCDR1, αCDR2, and KCDR1, βCDR2 and γCDR3 are colored yellow, orange, red,
green, blue and purple, respectively. Residues forming Fab-Fab contacts are labeled with the position of the Fab in the cryoEM model (A, B or C) indicated in subscript. mAb 3D11 affinity-matured residues that engage in Fab-Fab contacts, but do not directly interact with PbCSP are highlighted in yellow with red font. Black dashed lines denote H-bonds. (C) Sequence alignment of mAb 3D11 with its inferred germline precursor. INT1 and INT2 refer to the two interfaces shown in (A) and (B). Green highlight: germline-encoded residues involved in homotypic interactions; Red: affinity-matured residues involved in homotypic interactions; Yellow highlight: affinity-matured residues involved in homotypic interactions that do not directly interact with PbCSP. (D) Binding affinity of WT 3D11 and H-58/73 germline-reverted mutant (Mut) Fabs to NPNDx1 (gray bars) and NPNDx2 (white bars) peptides as measured by ITC. Symbols represent independent measurements. Mean K_D values resulting from at least two independent experiments are shown. Error bars represent standard error of the mean. An unpaired one-tailed t-test was performed using GraphPad Prism 8 to evaluate statistical significance: *p<0.05.

The online version of this article includes the following figure supplement(s) for figure 5:

**Figure supplement 1.** Homotypic contacts between 3D11 Fabs in the 3D11 Fab-PbCSP cryoEM structure.

**Figure supplement 2.** Negative-stain EM analysis of 3D11 IgG-PbCSP complexes.

**Figure supplement 3.** Comparison between cryoEM structures of 3D11 Fab-PbCSP and 311 Fab-PfCSP (PDB ID: 6MB3) (Oyen et al., 2018).

multiple Fab-Fab contacts in the cryoEM structure (**Figure 5** and **Figure 5—figure supplement 1**). Comparison of the mAb 3D11 sequence to its inferred germline precursor (IGHV1-12 and IGKV1-135) reveals that some of the residues involved in these homotypic contacts have been somatically hypermutated (H.Tyr50 and H.Val56 in HC DR2, H.Asn58 and H.Thr73 in heavy chain (HC) framework region (FR) 3, and K.Tyr27D in KC DR1, **Figure 5C**). While H.Tyr50, H.Val56 and K.Tyr27D mediate Fab-Fab contacts in addition to directly interacting with PbCSP, H.Asn58 and H.Thr73 are only involved in Fab-Fab interactions.

To investigate the role of affinity maturation in enhancing Fab-Fab contacts, somatically mutated HC residues H.Asn58 and H.Thr73 were reverted to their inferred germline precursors (N58S and T73K: subsequently named H-58/73; **Figure 5C**). Our findings are in agreement with a similar analysis previously performed with human 311 Fab and IgG in complex with PICSP (Oyen et al., 2018), which also observed the ability of both IgG and Fab to induce a spiral-like conformation in CSP.

**Discussion**

The CSP repeat is of broad interest for malaria vaccine design because it is targeted by inhibitory antibodies capable of preventing sporozoite infection as the parasite transits from Anopheles mosquitoes to mammalian hosts. Biophysical studies of the PICSP central NANP repeat have shown that...
this region possesses low secondary structure propensities (Dyson et al., 1990), and AFM studies on live Pf sporozoites suggest a range of conformations for PfCSP (Patra et al., 2017; Herrera et al., 2015). Importantly, recent studies have uncovered that some of the most potent antibodies against the PfCSP repeat region are cross-reactive with the PfCSP N-terminal junction, which harbors KQPA, NPDP and NVDP motifs interspersed with NANP motifs (Kisalu et al., 2018; Murugan et al., 2020; Tan et al., 2018). Our MD simulations of different sub-regions of the PfCSP central repeat, including the N-junction, provided detailed descriptions of their conformational ensemble and revealed that each sequence motif possesses a similarly low structural propensity.

Our MD simulations for PbCSP also indicated that the low structural propensity of central repeat motifs with subtle sequence variance extends to other Plasmodium species. These findings are in agreement with studies linking repetitive, low-complexity peptide sequences to structural disorder (Rauscher and Pomés, 2012; Rauscher and Pomés, 2017; Romero et al., 2001). The role of the numerous repetitive sequences observed in parasitic genomes (Tan et al., 2010; Mendes et al., 2013; Davies et al., 2017) remains to be fully understood, but is postulated to include maximizing parasite interactions with the target host cell (Mendes et al., 2013), allowing the parasite to adapt under selective pressure by varying its number of repeats (Davies et al., 2017), and impairing the host immune response (Ly and Hansen, 2019; Portugal et al., 2015; Sullivan et al., 2015).

Binding of the PICSP repeat by inhibitory antibodies has been shown to induce various conformations in this intrinsically disordered region (Imkeller et al., 2018; Kisalu et al., 2018; Murugan et al., 2020; Oyen et al., 2017; Tan et al., 2018; Triller et al., 2017; Scally and Julien, 2018; Pholcharee et al., 2020). Here, we show that the PbCSP repeat adopts an extended and bent conformation when recognized by inhibitory mAb 3D11. Antibody recognition of the PICSP repeat is often mediated by aromatic cages formed by the paratope, which surround prolines, backbone atoms, and aliphatic portions of side chains in the epitope (Murugan et al., 2020; Pholcharee et al., 2020). Antibody paratope residues partaking in aromatic cages often include germline-encoded residues, such as H.Trp52 from VH3-33 signature genes that are strongly recruited in the humoral response against PICSP (Julien and Wardemann, 2019; Pholcharee et al., 2020; Murugan et al., 2018). Similarly, murine mAb 3D11 uses eight aromatic residues to recognize the PbCSP repeat. Germline-encoded K.Tyr32 appears to play a central role in mAb 3D11 PbCSP recognition by contacting consecutive Asn-Asp-Pro residues (PN(A/P)NDP(A/P)P) in the middle of the core epitope, contributing 58 Å² of BSA on the Fab. These findings indicate a central role for germline-encoded aromatic residues in antibody binding of Plasmodium CSP repeats across species.

Our structural and biophysical data demonstrated that mAb 3D11 is cross-reactive and binds the different repeat motifs of PbCSP in nearly identical conformations. Such cross-reactivity for the repeat motifs of subtle differences in PICSP is also exhibited by inhibitory human antibodies encoded by a variety of Ig-gene combinations (Kisalu et al., 2018; Murugan et al., 2020; Tan et al., 2018; Triller et al., 2017; Scally et al., 2018). Notably, the inferred germline precursor genes of mAb 3D11 (IGHV1-12/IGKV1-135) share the most sequence similarity with the human IGHV1-3/IGKV2-30 genes (68% and 82% sequence identity, respectively); IGHV1-3 is the inferred germline precursor of the potent, cross-reactive human mAb CI543 (Kisalu et al., 2018). Moreover, it was previously reported that human anti-PfCSP antibody affinity is often directly associated with epitope cross-reactivity (Murugan et al., 2020). While mAb 3D11 provides one such example in mice, further investigation is needed to determine whether favorable selection of cross-reactive clones during B cell maturation has evolved as a common mechanism of the immune response in mammals against Plasmodium CSP.

Most residues that mediate mAb 3D11 contacts with the PbCSP repeat are germline-encoded; indeed, of nine affinity-matured residues in the HC and three in the KC, only three are involved in direct contacts with the antigen (H.Trp50, H.Val56 and K.Tyr27D). Due to the repetitive nature of the central repeat motifs, multiple antibodies bind simultaneously to one CSP protein and neighboring Fabs engage in homotypic interactions (Imkeller et al., 2018; Oyen et al., 2018). Our data suggest that somatic mutations of residues that partake in Fab-Fab contacts enhance homotypic interactions and indirectly improve the binding affinity of the mAb to CSP. In this respect, mAb 3D11 recognition of PbCSP resembles binding of some neutralizing human mAbs to PICSP (Imkeller et al., 2018; Murugan et al., 2020; Oyen et al., 2018). In human mAbs 311 (Oyen et al., 2018) and 1210 (Imkeller et al., 2018), CDR3 regions of both heavy and light chains appear to play a considerable role in forming Fab-Fab contacts. Interestingly, in the case of mAb 3D11, homotypic interactions are
mainly mediated by residues localized in HCDR1 and –2, KCDR1, and FR3 regions of both the HC and KC, with little contribution from residues in the CDR3 regions (with the exception of H.Tyr97 in HCDR3 and K.Phe94 in KCDR3). Taken together, these findings indicate that homotypic interactions are a feature by which the mammalian immune system can robustly engage repetitive Plasmodium antigens with high affinity in various ways. Interestingly, recent studies have reported that Fab-Fab interactions occur in other antibody-antigen complexes, providing evidence that homotypic contacts can drive diverse biology: for example, homotypic interactions were found between two nanobodies bound to a pentameric antigen (Bernedo-Navarro et al., 2018), and between two Rituximab antibodies bound to B cell membrane protein CD20 (Rougé et al., 2020).

Our cryoEM analysis also revealed how the PbCSP repeat, like that of PfCSP, can adopt a highly organized spiral structure upon mAb binding. Such spiral assembly of CSP was previously observed upon human mAb 311 Fab and IgG binding, which induced a PfCSP spiral with a greater diameter (27 Å) and smaller pitch (49 Å) compared to the 3D11-PbCSP complex (16 Å diameter and 51 Å pitch) (Oyen et al., 2018; Figure 5—figure supplement 3). Differences in the architecture between these two complexes can be attributed to the fact that mAbs 3D11 and 311 recognize their respective antigens in distinct conformations. Because different anti-CSP inhibitory antibodies can bind the repeat region in a variety of conformations (Imkeller et al., 2018; Kisalu et al., 2018; Tan et al., 2018; Triller et al., 2017; Scally and Julien, 2018), it is likely that many types of CSP-antibody assemblies exist. Further studies are needed to investigate whether the formation of such highly organized complexes is possible on the surface of live sporozoites and how antibody-CSP interactions occur in the context of polyclonal serum. These insights will be important for our structure-function understanding of the mechanisms employed by these repeat-targeting antibodies to inhibit sporozoite development, migration and infection of hepatocytes.

### Materials and methods

**Key resources table**

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Recombinant DNA reagent           | pcDNA3.4-3D11 Fab HC (plasmid) | This paper | N/A | 3D11 Fab heavy chain gene in pcDNA3.4 TOPO vector |
| Recombinant DNA reagent           | pcDNA3.4-3D11 Fab 58/73 HC (plasmid) | This paper | N/A | 3D11 Fab germline-reverted mutant heavy chain gene in pcDNA3.4 TOPO vector |
| Recombinant DNA reagent           | pcDNA3.4-3D11 Fab KC (plasmid) | This paper | N/A | 3D11 Fab light chain gene in pcDNA3.4 TOPO vector |
| Recombinant DNA reagent           | pcDNA3.4-PbCSP-6xHis (plasmid) | This paper | N/A | PbCSP gene with His tag in pcDNA3.4 TOPO vector |
| Recombinant DNA reagent           | pcDNA3.4-Pb-CSP-6xHis (plasmid) | This paper | N/A | PbCSP gene with His tag in pcDNA3.4 TOPO vector |
| Recombinant DNA reagent           | pcDNA3.4-Pb-CSP-αTSR-6xHis (plasmid) | This paper | N/A | PbCSP αTSR gene with His tag in pcDNA3.4 TOPO vector |
| Cell line (Homo sapiens)          | FreeStyle 293 F cells | Thermo Fisher Scientific | Cat# R79007 |
| Cell line (Mus musculus)          | 3D11 hybridoma cell line | Yoshida et al., 1980 | BEI Resources #MRA-100; RRID:AB_2650479 |
| Chemical compound                 | GIBCO FreeStyle 293 Expression Medium | Thermo Fisher Scientific | Cat# 12338026 |
| Chemical compound                 | GIBCO Hybridoma-SFM | Thermo Fisher Scientific | Cat# 12045076 |
| Chemical compound                 | FectoPRO DNA Transfection Reagent | VWR  | Cat# 10118-444 |
| Chemical compound                 | Fetal bovine serum | Thermo Fisher Scientific | Cat# 12483-020 |
| Antibody                          | 3D11 IgG (mouse monoclonal) | Yoshida et al., 1980 | N/A | Purified from 3D11 hybridoma cell line; See Materials and methods |

**Continued on next page**
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Recombinant protein               | 3D11 Fab    | This paper          | N/A         | See Materials and methods for concentrations and masses used, and buffer conditions |
| Recombinant protein               | 3D11 Fab H-58/73 | This paper          | N/A         | See Materials and methods for concentrations and masses used, and buffer conditions |
| Recombinant protein               | PbCSP       | This paper          | N/A         | See Materials and methods for concentrations and masses used, and buffer conditions |
| Peptide                           | PAPP (PAPPNANDPAPPNAND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Peptide                           | NAND (PPPPNANDPPPPNAND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Peptide                           | NPND (PPPPNPNDPPPPNPND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Peptide                           | Mixed (PPPPNPNDPAPPNAND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Peptide                           | NPNDx1 (PPPPNPNDPPPPNPND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Peptide                           | NPNDx2 (PPPPNPNDPPP NPNDPPPNNPND) | This paper          | N/A         | Derived from PbCSP repeat region |
| Software, algorithm               | GROMACS 5.1.4 | Abraham et al., 2015; Berendsen et al., 1995 | http://manual.gromacs.org/documentation/5.1.4/; RRID:SCR_014565 |
| Software, algorithm               | LINCS       | Hess et al., 1997;  Hess, 2008 | N/A |
| Software, algorithm               | Particle-Mesh Ewald algorithm | Darden et al., 1993; Essmann et al., 1995 | N/A |
| Software, algorithm               | Nosé-Hoover thermostat | Nosé, 1984; Hoover, 1985 | N/A |
| Software, algorithm               | Parrinello-Rahman algorithm | Parrinello and Rahman, 1981 | N/A |
| Software, algorithm               | VMD         | Humphrey et al., 1996 | https://www.ks.uiuc.edu/Research/vmd/; RRID:SCR_001820 |
| Software, algorithm               | Matplotlib  | Hunter, 2007        | https://matplotlib.org/; RRID:SCR_008624 |
| Software, algorithm               | Octet Data Analysis Software 9.0.0.6 | ForteBio | https://www.fortebio.com/products/octet-systems-software |
| Software, algorithm               | MicroCal ITC Origin 7.0 Analysis Software | Malvern | https://www.malvernpanalytical.com/ |
| Software, algorithm               | ASTRA       | Wyatt               | https://www.wyatt.com/products/software/astra.html; RRID:SCR_016255 |
| Software, algorithm               | GraphPad Prism 8 | GraphPad Software | https://www.graphpad.com/; RRID:SCR_002798 |
| Software, algorithm               | EPU         | ThermoFisher Scientific | https://www.fei.com/software/ |
| Software, algorithm               | SBGrid      | SBGrid Consortium   | https://sbgrid.org/; RRID:SCR_003511 |
| Software, algorithm               | cryoSPARC v2 | Punjani et al., 2017 | https://cryosparc.com/ |
| Software, algorithm               | Phenix      | Adams et al., 2010  | https://www.phenix-online.org/; RRID:SCR_014224 |

Continued on next page
Continued

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Software, algorithm               | UCSF Chimera | Pettersen et al., 2004 | https://www.cgl.ucsf.edu/chimera/; RRID:SCR_004097 |
| Software, algorithm               | UCSF ChimeraX | Goddard et al., 2018 | https://www.cgl.ucsf.edu/chimerax/; RRID:SCR_015872 |
| Software, algorithm               | Coot        | Emsley et al., 2010 | https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/; RRID:SCR_014222 |
| Software, algorithm               | PyMOL       | The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC. | https://pymol.org/2/#products; RRID:SCR_000305 |
| Other                             | Homemade holey gold grids | Marr et al., 2014 | N/A |
| Other                             | Homemade carbon grids | Booth et al., 2011 | N/A |

**Molecular dynamics simulations**

We performed all-atom molecular dynamics simulations of the following peptides: (NPNA)$_5$, K QPADGNPDNPANPNP, NPDPNANPVDPNANP, (NVDPNANP)$_2$NVDP, (PPPNPNPD)$_2$, (PPPNNPND)$_2$, and PPPNPNDPAPPND as blocked monomers in water with 0.15 M NaCl. Each simulation system consisted of the respective peptide with an acetylated N-terminus and amidated C-terminus solvated in a dodecahedral box with side lengths of 4.9 nm.

The systems were simulated using the program GROMACS 5.1.4 (67, 68) with the CHARMM22* (Piana et al., 2011; Best and Hummer, 2009; Lindorff-Larsen et al., 2012; Best and Mittal, 2010; MacKerell et al., 1998) force field for the protein and the TIP3P (Jorgensen et al., 1983) water model. All simulations were performed with periodic boundary conditions at a constant pressure and temperature of 1 bar and 300 K, respectively. The LINCS algorithm was used to constrain all bond lengths (Hess et al., 1997; Hess, 2008). A cut-off of 1.4 nm was used for Lennard-Jones interactions. The Particle-Mesh Ewald algorithm (Darden et al., 1993; Essmann et al., 1995) was used to calculate long-range electrostatics interactions with a Fourier spacing of 0.12 and an interpolation order of 4. The Nosé-Hoover thermostat (Nosé, 1984; Hoover, 1985) was used for temperature coupling with the peptide and solvent coupled to two temperature baths and a time constant of 0.1 ps. The Parrinello-Rahman algorithm (Parrinello and Rahman, 1981) was used for pressure coupling with a time constant of 2 ps. The integration step size was two fs and the system coordinates were stored every 10 ps.

The simulations were performed for 300 ns for 20 independent replicas of (NPNA)$_5$ and 10 independent replicas of all other sequences. The initial structures of the peptides were selected from 10 ns simulations in which extended conformations of the peptides were collapsed in vacuo. The first 100 ns of each trajectory were omitted as the time required for system relaxation based on the convergence analysis of the radius of gyration (Rg) shown in Figure 1—figure supplement 2. This protocol resulted in a total of 4 μs of production time for the (NPNA)$_5$ dataset and a total of 2 μs of production time for the other systems, which was used to compute equilibrium ensemble properties. The peptide snapshots were generated with VMD (Humphrey et al., 1996) and the plots were created with Matplotlib (Hunter, 2007).

**3D11 Fab production and purification**

The mAb 3D11 hybridoma cell line variable light and heavy chain antibody genes were sequenced (Applied Biological Materials Inc). mAb 3D11 V$_k$ and V$_H$ regions were cloned individually into custom pcDNA3.4 expression vectors immediately upstream of human Igκ and Igγ1-C$_H$1 domains,
respectively. The resulting pcDNA3.4-3D11 Fab KC and –3D11 Fab HC or –3D11 Fab 58/73 HC plasmids were co-transfected into FreeStyle 293 F cells for transient expression using FectoPRO DNA Transfection Reagent, cultured in GIBCO FreeStyle 293 Expression Medium, and purified via KappaSelect affinity chromatography (GE Healthcare), cation exchange chromatography (MonoS, GE Healthcare), and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).

3D11 IgG production and purification
The mAb 3D11 hybridoma cell line (BEI Resources MRA-100) was cultured in GIBCO Hybridoma-SFM (Thermo Fisher Scientific Cat#12045076) with 2.5–10% fetal bovine serum (Thermo Fisher Scientific Cat#12483–020). Cells were harvested and the supernatant containing 3D11 IgG was purified via Protein G affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superose 6 Increase 10/300 GL, GE Healthcare).

Recombinant PbCSP production and purification
Constructs of full-length PbCSP (residues 24–318), the PbCSP C-terminal domain (residues 202–318; PbC-CSP) and the PbCSP αTSR domain (residues 263–318; PbCSP αTSR) from strain ANKA (NCBI reference sequence XP_022712148.1) were designed with potential N-linked glycosylation sites mutated to glutamine and cloned into pcDNA3.4 expression vectors with a His tag. The resulting pcDNA3.4-PbCSP-6xHis, -PbC-CSP-6xHis and -PbCSP-αTSR-6xHis plasmids were transiently transfected in FreeStyle 293 F cells using FectoPRO DNA Transfection Reagent, cultured in GIBCO FreeStyle 293 Expression Medium, and purified by HisTrap FF affinity chromatography (GE Healthcare) and size-exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare).

Cell lines
FreeStyle 293 F cells (Thermo Fisher Scientific 12338026) and 3D11 hybridoma cell line (BEI Resources MRA-100) were authenticated and validated to be mycoplasma-free by their respective commercial entities.

Binding kinetics by biolayer interferometry
BLI (Octet RED96, ForteBio) experiments were conducted to determine the binding kinetics of the 3D11 Fab to recombinant PbCSP. PbCSP, PbC-CSP or PbCSP αTSR was diluted to 10 μg/ml in kinetics buffer (PBS, pH 7.4, 0.01% [w/v] BSA, 0.002% [v/v] Tween-20) and immobilized onto Ni-NTA (NTA) biosensors (ForteBio). After a steady baseline was established, biosensors were dipped into wells containing twofold dilutions of 3D11 Fab in kinetics buffer. Tips were then immersed back into kinetics buffer for measurement of the dissociation rate. Kinetics data were analyzed using the ForteBio's Octet Data Analysis software 9.0.0.6, and curves were fitted to a 2:1 binding model.

Binding thermodynamics by isothermal titration calorimetry
Calorimetric titration experiments were performed with an Auto-iTC200 instrument (Malvern) at 37°C. Full-length PbCSP and PbCSP-derived peptides (PAPP, NAND, NPND, Mixed, NPNDx1, NPNDx2; GenScript) were diluted in Tris-buffered saline (TBS; 20 mM Tris pH 8.0, and 150 mM NaCl) and added to the calorimetric cell. Titrations were performed with 3D11 Fab in the syringe, diluted in TBS, in 15 successive injections of 2.5 μl. Full-length PbCSP was diluted to 5 μM and titrated with 3D11 Fab at 400 μM. All PbCSP-derived peptides were diluted to 20 μM and titrated with 3D11 Fab at 200–300 μM; with the exception of the NPNDx2 peptide, which was diluted to 9–10 μM and titrated with 180–200 μM 3D11 Fab. Experiments were performed at least two times, and the mean and standard error of the mean are reported. The experimental data were analyzed using the MicroCal ITC Origin 7.0 Analysis Software according to a 1:1 binding model.

Size-exclusion chromatography-multi-angle light scattering (SEC-MALS)
Full-length PbCSP was complexed with a molar excess of 3D11 Fab and loaded on a Superose 6 Increase 10/300 GL (GE Healthcare) using an Agilent Technologies 1260 Infinity II HPLC coupled inline with the following calibrated detectors: (i) MiniDawn Treos MALS detector (Wyatt); (ii)
Quasielastic light scattering (QELS) detector (Wyatt); and (iii) Optilab T-reX refractive index (RI) detector (Wyatt). Data processing was performed using the ASTRA software (Wyatt).

Crystallization and structure determination

Purified 3D11 Fab was concentrated and diluted to 5 mg/mL with each of the PAPP, NAND and Mixed peptides in a 1:5 molar ratio; and diluted to 2.1 mg/mL with the NPND peptide in a 1:5 molar ratio. The 3D11 Fab/PAPP complex was mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.15 M malic acid pH 7. Crystals appeared after ~1 d and were cryoprotected in 15% (v/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/NAND complex was mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.2 M di-sodium tartrate. Crystals appeared after ~3 d and were cryoprotected in 15% (v/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/NPND complex was mixed in a 1:1 ratio with 25% (w/v) PEG 3350, 0.2 M lithium sulfate, 0.1 M Tris pH 8.5. Crystals appeared after ~12 d and were cryoprotected in 20% (w/v) ethylene glycol before being flash-frozen in liquid nitrogen. The 3D11 Fab/Mixed complex was mixed in a 1:1 ratio with 25.5% (w/v) PEG 4000, 15% (v/v) glycerol, 0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6. Crystals appeared after ~1 d and were cryoprotected in 20% (v/v) glycerol before being flash-frozen in liquid nitrogen.

Data were collected at the 23-ID-D or 23-ID-B beamline at the Argonne National Laboratory Advanced Photon Source, or at the 17-ID-1 beamline at the National Synchrotron Light Source II. All datasets were processed and scaled using XDS (Kabsch, 2010). The structures were determined by molecular replacement using Phaser (McCoy et al., 2007). Refinement of the structures was performed using phenix.refine (Adams et al., 2010) and iterations of refinement using Coot (Emsley et al., 2010). Access to all software was supported through SBGrid (Morin et al., 2013).

CryoEM data collection and image processing

The PbCSP/3D11 complex was concentrated to 3 mg/mL and incubated briefly with 0.01% (w/v) n-Dodecyl β-D-maltopyranoside. 3 μl of the sample was deposited on homemade holey gold grids (Marr et al., 2014), which were glow-discharged in air for 15 s before use. Sample was blotted for 12.5 s, and subsequently plunge-frozen in a mixture of liquid ethane and propane (Tivol et al., 2008) using a modified FEI Vitrobot (maintained at 4°C and 100% humidity). Data collection was performed on a Thermo Fisher Scientific Titan Krios G3 operated at 300 kV with a Falcon 3EC camera automated with the EPU software. A nominal magnification of 75,000 × (calibrated pixel size of 1.06 Å) and defocus range between 1.6 and 2.2 μm were used for data collection. Exposures were fractionated as movies of 30 frames with a total exposure of 42.7 electrons/A2. A total of 2080 raw movies were obtained.

Image processing was carried out in cryoSPARC v2 (Punjani et al., 2017). Initial specimen movement correction, exposure weighting, and CTF parameters estimation were done using patch-based algorithms. Manual particle selection was performed on 30 micrographs to create templates for template-based picking. 669,223 particle images were selected by template picking and individual particle images were corrected for beam-induced motion with the local motion algorithm (Rubinstein and Brubaker, 2015). Ab-initio structure determination revealed that most particles present in the dataset correspond to the 3D11 Fab-PbCSP complex, with a minor population of particles corresponding to unbound 3D11 Fab. After several rounds of heterogeneous refinement, 165,747 particle images were selected for non-uniform refinement with no symmetry applied, which resulted in a 3.2 Å resolution map of the 3D11 Fab-PbCSP complex estimated from the gold-standard Fourier shell correlation (FSC) criterion.

CryoEM model building

To create a starting model of the 3D11 Fab-PbCSP complex, seven copies of 3D11 Fab/PbCSP-peptide crystal structures were manually docked into the 3D11 Fab-PbCSP cryoEM map using UCSF Chimera (Pettersen et al., 2004), followed by manual building using Coot (Emsley et al., 2010). All models were refined using phenix.real_space_refine (Adams et al., 2010) with secondary structure and geometry restraints. The final models were evaluated by MolProbity (Chen et al., 2010). The figures were prepared with UCSF Chimera (Pettersen et al., 2004) and UCSF ChimeraX.
Negatives-stain EM of 3D11 IgG-PbCSP complex
To obtain soluble complexes of 3D11-IgG-PbCSP for NS analysis, 8.4 µg of PbCSP was incubated overnight with 20x molar excess of 3D11 IgG. After removal of aggregates via centrifugation, 3D11 IgG-PbCSP complexes were purified on a Superose 6 Increase 10/300 GL column (GE Healthcare). Fractions containing complexes of 3D11 IgG-PbCSP were pooled and concentrated, and subsequently deposited at approximately 50 µg/mL onto homemade carbon grids and stained with 2% uranyl formate. Data were collected with a FEI Tecnai T20 electron microscope operating at 200 kV, and acquired with an Orius charge-coupled device (CCD) camera (Gatan Inc) at a calibrated 34,483X magnification, resulting in a pixel size of 2.71 Å. Particle picking, extraction and three rounds of 2D classification with 50 classes allowed were performed with cryoSPARC v2 (Punjani et al., 2017).

Acknowledgements
We are grateful to Dr. Samir Benlekbir for help with cryoEM data collection and for advice regarding specimen preparation. We thank Dr. Stephen Scally for his input during the course of this work. This work was supported by the CIFAR Azrieli Global Scholar program (JPJ), the Ontario Early Researcher Award program (JPJ), the Canada Research Chair program (JPJ and JLR), and the Canadian Institutes of Health Research (RP). I.K. was supported by a SickKids Restracomp Fellowship, E.T. by a CIHR Canada Graduate Scholarship, and A.S. by an NSERC Canada Graduate Scholarship and a SickKids Restracomp Scholarship. This research was enabled in part by support provided by Compute Ontario (https://computeontario.ca/) and Compute Canada (https://www.computecanada.ca/). The ITC and BLI instruments were accessed at the Structural and Biophysical Core Facility, The Hospital for Sick Children, supported by the Canada Foundation for Innovation and Ontario Research Fund. CryoEM data was collected at the Toronto High Resolution High Throughput cryoEM facility, supported by the Canada Foundation for Innovation and Ontario Research Fund. X-ray diffraction experiments were performed at GM/CA@APS, which has been funded in whole or in part with federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). The Eiger 16M detector was funded by an NIH–Office of Research Infrastructure Programs High-End Instrumentation grant (1510OD012289-01A1). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science user facility operated for the DOE Office of Science by Argonne National Laboratory under contract DE-AC02-06CH11357. X-ray diffraction experiments were also performed at the National Synchrotron Light Source II, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Brookhaven National Laboratory under Contract No. DE-SC0012704. The Life Science Biomedical Technology Research resource is primarily supported by the National Institute of Health, National Institute of General Medical Sciences (NIGMS) through a Biomedical Technology Research Resource P41 grant (P41GM111244), and by the DOE Office of Biological and Environmental Research (KP1605010). The following reagent was obtained through BEI Resources, NIAID, NIH: Hybridoma 3D11 Anti-Plasmodium berghei 44-Kilodalton Sporozoite Surface Protein (Pb44), MRA-100, contributed by Victor Nussenzweig. X-ray crystallography and cryoEM data and structures are accessible from the Protein Data Bank and the Electron Microscopy Data Bank under PDB IDs 6X8P, 6X8Q, 6X8S, 6X8U and 6X87, and EMDB 22089, respectively.

Additional information

Funding

| Funder                                | Grant reference number          | Author                  |
|---------------------------------------|---------------------------------|-------------------------|
| Canadian Institute for Advanced Research | Azrieli Global Scholar program | Jean-Philippe Julien    |
| Ontario Ministry of Economic Development, Job Creation and Trade |                                | John L Rubinstein      |
|                                       |                                 | Jean-Philippe Julien    |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Iga Kucharska, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing; Elaine Thai, Ananya Srivastava, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing; John L Rubinstein, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - review and editing; Régis Pomès, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing; Jean-Philippe Julien, Conceptualization, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing

Author ORCIDs
Iga Kucharska [https://orcid.org/0000-0001-6150-3419](https://orcid.org/0000-0001-6150-3419)
Elaine Thai [https://orcid.org/0000-0001-7576-154X](https://orcid.org/0000-0001-7576-154X)
John L Rubinstein [http://orcid.org/0000-0003-0566-2209](http://orcid.org/0000-0003-0566-2209)
Régis Pomès [http://orcid.org/0000-0003-3068-9833](http://orcid.org/0000-0003-3068-9833)
Jean-Philippe Julien [https://orcid.org/0000-0001-7602-3995](https://orcid.org/0000-0001-7602-3995)

Decision letter and Author response
Decision letter [https://doi.org/10.7554/eLife.59018.sa1](https://doi.org/10.7554/eLife.59018.sa1)
Author response [https://doi.org/10.7554/eLife.59018.sa2](https://doi.org/10.7554/eLife.59018.sa2)

Additional files

**Supplementary files**
- Supplementary file 1. Hydrogen-bonding propensities from simulations of peptides in solution. (A) Hydrogen-bonding propensity for each simulated motif and lifetime of each β-turn for the four PfCSP-derived peptides. (B) Hydrogen-bonding propensity for each simulated motif and lifetime of each β-turn for the four PbCSP-derived peptides.
- Supplementary file 2. Table of contacts between 3D11 Fab and PbCSP peptides. Rows are shaded according to the number of times interactions are observed between all four crystal structures, summed in the final column.
- Supplementary file 3. Table of contacts between one of the 3D11 Fabs and PbCSP in the cryoEM.
- Transparent reporting form
Data availability
X-ray crystallography and cryoEM data and structures have been deposited to the Protein Data Bank and the Electron Microscopy Data Bank.

The following datasets were generated:

| Author(s)       | Year | Dataset title                                                                 | Dataset URL                        | Database and Identifier         |
|-----------------|------|-------------------------------------------------------------------------------|------------------------------------|---------------------------------|
| Thai E, Julien JP | 2020 | Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein PAPP peptide | http://www.rcsb.org/structure/6X8Q | RCSB Protein Data Bank, 6X8Q  |
| Thai E, Julien JP | 2020 | Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NAND peptide | http://www.rcsb.org/structure/6X8S | RCSB Protein Data Bank, 6X8S  |
| Thai E, Julien JP | 2020 | Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein NPND peptide | http://www.rcsb.org/structure/6X8P | RCSB Protein Data Bank, 6X8P  |
| Thai E, Julien JP | 2020 | Crystal structure of 3D11 Fab in complex with Plasmodium berghei circumsporozoite protein Mixed peptide | http://www.rcsb.org/structure/6X8U | RCSB Protein Data Bank, 6X8U  |
| Kucharska I, Thai E, Rubinstein J, Julien JP | 2020 | CryoEM structure of the Plasmodium berghei circumsporozoite protein in complex with inhibitory mouse antibody 3D11 | http://www.rcsb.org/structure/6X87 | RCSB Protein Data Bank, 6X87  |
| Kucharska I, Thai E, Rubinstein J, Julien JP | 2020 | CryoEM structure of the Plasmodium berghei circumsporozoite protein in complex with inhibitory mouse antibody 3D11 | http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-22089 | Electron Microscopy Data Bank, 22089 |

References
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. 2015. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2:19–25. DOI: https://doi.org/10.1016/j.softx.2015.06.001
Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D Biological Crystallography 66:213–221. DOI: https://doi.org/10.1107/S0907444909052925, PMID: 20124702
Adepoju P. 2019. RTS,S malaria vaccine pilots in three african countries. The Lancet 393:1685. DOI: https://doi.org/10.1016/S0140-6736(19)30937-7
Berendsen HJC, van der Spoel D, van Drunen R. 1995. GROMACS: a message-passing parallel molecular dynamics implementation. Computer Physics Communications 91:43–56. DOI: https://doi.org/10.1016/0010-4655(95)00042-E
Bernedo-Navarro R, Romao E, Yano T, Pinto J, De Greve H, Sterckx Y, Mylndermans S. 2018. Structural basis for the specific neutralization of Stx2a with a camelid single domain antibody fragment. Toxins 10:108. DOI: https://doi.org/10.3390/toxins10030108
Best RB, Hummer G. 2009. Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides. The Journal of Physical Chemistry B 113:9004–9015. DOI: https://doi.org/10.1021/jp901540t, PMID: 19514729
Best RB, Mittal J. 2010. Protein simulations with an optimized water model: cooperative Helix formation and Temperature-Induced unfolded state collapse. The Journal of Physical Chemistry. 8 114:14916–14923. DOI: https://doi.org/10.1021/jp101861d, PMID: 21038907
Booth DS, Avila-Sakar A, Cheng Y. 2011. Visualizing proteins and macromolecular complexes by negative stain EM: from grid preparation to image acquisition. Journal of Visualized Experiments 22:3227. DOI: https://doi.org/10.3791/3227
Cerami C, Fresvert U, Sinnis P, Takacs B, Clavijo P, Santos MJ, Nussenzweig V. 1992. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70:1021–1033. DOI: https://doi.org/10.1016/0092-8674(92)90251-7, PMID: 1326407
Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D Biological Crystallography 66:12–21. DOI: https://doi.org/10.1107/S0907444909042073

PMID: 20057044

Chenet SM, Tapia LL, Escalante AA, Durand S, Lucas C, Bacon DJ. 2012. Genetic diversity and population structure of genes encoding vaccine candidate antigens of plasmodium vivax. Malaria Journal 11:68. DOI: https://doi.org/10.1186/1475-2875-11-68

PMID: 22417572

Cochrane AH, Aikawa M, Jeng M, Nussenzeew RS. 1976. Antibody-induced ultrastructural changes of malarial sporozoites. Journal of Immunology 116:859–867. PMID: 815435

Cui L, Maharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. 2015. Antimalarial drug resistance: literature review and activities of the IECMR network. The American Journal of Tropical Medicine and Hygiene 93:57–68. DOI: https://doi.org/10.4269/ajtmh.15-0007

PMID: 26299943

Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Maloy WL, Haynes JD, Schneider R. 1984. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225:593–599. DOI: https://doi.org/10.1126/science.6204383

PMID: 6204383

Darden T, York D, Pedersen L. 1993. Particle mesh Ewald: An N · log N method for Ewald sums in large systems. The Journal of Chemical Physics 98:10089–10092. DOI: 10.1063/1.464397

PMID: 815435

De Niz M, Heussler VT. 2018. Rodent malaria models: insights into human disease and parasite biology. Current Opinion in Microbiology 46:93–101. DOI: https://doi.org/10.1016/j.mib.2018.09.003

PMID: 30317152

Dobaño C, Sanz H, Sorgo H, Dosoo D, Mpina M, Ubillos I, Aguilar R, Ford T, Diez-Padría N, Williams NA, Ayestaran A, Traore O, Nhabomba AJ, Jairoce C, Waitumbi J, Añandjji ST, Kariuki S, Abdulla S, Aponte JJ, Roberts D. 2018. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications 10:2174. DOI: https://doi.org/10.1038/s41467-019-10195-z

PMID: 31092823

Doolan DL. 2011. Plasmodium immunomics. International Journal for Parasitology 41:1–20. DOI: https://doi.org/10.1016/j.ijpara.2010.08.002

PMID: 20816843

Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, Long CA, Seder RA. 2018. Malaria vaccines: recent advances and new horizons. Cell Host & Microbe 24:43–56. DOI: 10.1016/j.chom.2018.06.008

PMID: 30001524

Dyson HJ, Satterthwait AC, Lerner RA, Wright PE. 1990. Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of Plasmodium falciparum by 1H NMR. Biochemistry 29:7828–7837. DOI: https://doi.org/10.1021/bi00486a008

PMID: 2261440

Eichinger DJ, Arnot DE, Tam JP, Nussenzweig V, Enea V. 1986. Circumsporozoite protein of plasmodium berhei: gene cloning and identification of the immunodominant epitopes. Molecular and Cellular Biology 6:3965–3972. DOI: https://doi.org/10.1128/MCB.6.11.3965

PMID: 2432395

Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of coot. Acta Crystallographica. Section D, Biological Crystallography 66:486–501. DOI: https://doi.org/10.1107/S0907444910007493

PMID: 20383002

Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. 1995. A smooth particle mesh ewald method. The Journal of Chemical Physics 103:8577–8593. DOI: https://doi.org/10.1063/1.470117

Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, Nussenzweig V. 1993. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. Journal of Experimental Medicine 177:1287–1298. DOI: https://doi.org/10.1084/jem.177.5.1287

PMID: 8478608

Ghasparian A, Moehle K, Linden A, Robinson JA. 2006. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem. Commun. 365:174–176. DOI: https://doi.org/10.1039/B510812H

PMID: 18034872

Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JJ, Ferrin TE. 2018. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Science 27:14–25. DOI: https://doi.org/10.1002/pro.3235

PMID: 28710774

Hall BF, Fauci AS. 2009. Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda. The Journal of Infectious Diseases 200:1639–1643. DOI: https://doi.org/10.1086/646611

PMID: 19877843

Herrera R, Anderson C, Kumar K, Molina-Cruz A, Nguyen V, Burkhartd M, Reiter K, Shimp R, Howard RF, Srinivasan P, Nold MJ, Ragheb D, Shi L, DeCotiis M, Aebig J, Lambre J, Rausch KM, Muratova O, Jin A, Reed SG, et al. 2015. Reversible conformational change in the Plasmodium falciparum circumsporozoite protein masks its adhesion domains. Infection and Immunity 83:3771–3780. DOI: https://doi.org/10.1128/IAI.02676-14

PMID: 26169272
et al. eLife 2020;9:e59018. DOI: https://doi.org/10.7554/eLife.59018

Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. 1997. LINCS: a linear constraint solver for molecular simulations. Journal of Computational Chemistry 18:1463–1472. DOI: https://doi.org/10.1002/(SICI)1096-987X(199709)18:14<1463::AID-JCC4>3.0.CO;2-H

Hess B. 2008. P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation. Journal of Chemical Theory and Computation 4:116–122. DOI: https://doi.org/10.1021/ct070020b, PMID: 26619985

Hvoorweg WG. 1985. Canonical dynamics: equilibrium phase-space distributions. Physical Review A 31:1695–1697. DOI: https://doi.org/10.1103/PhysRevA.31.1695

Humphrey W, Dalke A, Schulten K. 1996. VMD: Visual molecular dynamics. Journal of Molecular Graphics 14:33–38. DOI: https://doi.org/10.1016/0263-7855(96)00018-5

Hunter JD. 2007. Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering 9:90–95. DOI: https://doi.org/10.1109/MCSE.2007.55

Illingworth JJ, Alanine DG, Brown R, Marshall JM, Bartlett HE, Silk SE, Labbé GM, Quinkert D, Cho JS, Wendler JP, Pattinson DJ, Barford L, Douglas MW, Shea MW, Wright KE, de Cassan SC, Higgins MK, Draper SJ. 2019. Functional comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens. Frontiers in Immunology 10:1254. DOI: https://doi.org/10.3389/fimmu.2019.01254, PMID: 31214195

Imkeller K, Scally SW, Bosch A, Marti GP, Costa G, Triller G, Murugan R, Renna V, Jumaa H, Kremsner PG, Sim BKL, Hoffman SL, Mordmüller B, Levashina EA, Julien JP, Wardemann H. 2018. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360:1358–1362. DOI: https://doi.org/10.1126/science.aar5304, PMID: 29880723

Jørgensen WL, Chandrasekar J, Madura JD, Imprey RW, Klein ML. 1983. Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 79:926–935. DOI: https://doi.org/10.1063/1.445869

Julien JP, Wardemann H. 2019. Antibodies against Plasmodium falciparum malaria at the molecular level. Nature Reviews Immunology 19:761–775. DOI: https://doi.org/10.1038/s41577-019-0209-5, PMID: 31462718

Kabsch W. 2010. XDS. Acta Crystallographica. Section D, Biological Crystallography 66:125–132. DOI: https://doi.org/10.1107/S0907444909047337, PMID: 20124692

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, et al. 2018. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine 24:408–416. DOI: https://doi.org/10.1038/nm.4512, PMID: 29554083

Krissinel E, Henckik K. 2007. Inference of macromolecular assemblies from crystalline state. Journal of Molecular Biology 372:774–797. DOI: https://doi.org/10.1016/j.jmb.2007.05.022, PMID: 17681537

Lindorff-Larsen K, Maragakis P, Piana S, Eastwood MP, Dror RO, Shaw DE. 2012. Systematic validation of protein force fields against experimental data. PLOS ONE 7:e32131. DOI: https://doi.org/10.1371/journal.pone.0032131, PMID: 22384157

Lover AA, Baird JK, Gosling R, Price RN. 2018. Malaria elimination: time to target all species. The American Journal of Tropical Medicine and Hygiene 99:17–23. DOI: https://doi.org/10.4269/ajtmh.18-0669, PMID: 29761762

Ly A, Hansen DS. 2019. Development of B cell memory in malaria. Frontiers in Immunology 10:559. DOI: https://doi.org/10.3389/fimmu.2019.00559, PMID: 31001244

MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczerka K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reihner WE, et al. 1998. All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. The Journal of Physical Chemistry B 102:3586–3616. DOI: https://doi.org/10.1021/jp973084f

Marr CR, Benlekib S, Rubinstein JL. 2014. Fabrication of carbon films with ~500nm holes for cryo-EM with a direct detector device. Journal of Structural Biology 185:42–47. DOI: https://doi.org/10.1016/j.jsb.2013.11.002

McCall MBB, Kremsner PG, Mordmüller B. 2018. Correlating efficacy and immunogenicity in malaria vaccine trials. Seminars in Immunology 39:52–64. DOI: https://doi.org/10.1016/j.smim.2018.08.002

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. Journal of Applied Crystallography 40:658–674. DOI: https://doi.org/10.1107/S0021889807021206

Ménard R, Sultan AA, Cortes C, Altzusler R, van Dijk MR, Janse CJ, Waters AP, Nussenzweig RS, Nussenzweig V. 1997. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385:330–334. DOI: https://doi.org/10.1038/385330a0, PMID: 9002517

Mendes TAO, Lobo FP, Rodrigues TS, Rodrigues-Luiz GF, da Rocha WD, Fujiwara RT, Teixeira SMR, Bartholomeu DC. 2013. Repeat-Enriched Proteins Are Related to Host Cell Invasion and Immune Evasion in Parasitic Protozoa. Molecular Biology and Evolution 30:951–963. DOI: https://doi.org/10.1093/molbev/msn001

Mishra S, Nussenzweig RS, Nussenzweig V. 2012. Antibodies to plasmodium circumsporozoite protein (CSP) inhibit sporozoite’s cell traversal activity. Journal of Immunological Methods 377:47–52. DOI: https://doi.org/10.1016/j.jim.2012.01.009, PMID: 22306356

Morin A, Eisenbraun B, Key J, Sanschagrin PC, Timony MA, Ottaviano M, Sliz P. 2013. Collaboration gets the most out of software. eLife 2:e01456. DOI: https://doi.org/10.7554/eLife.01456, PMID: 24040512

Murugan R, Buchauer L, Triller G, Kreschel C, Costa G, Pidelaserra Marti G, Imkeller K, Busse CE, Chakravarty S, Sim BKL, Hoffman SL, Levashina EA, Kremsner PG, Mordmüller B, Höfer T, Wardemann H. 2018. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Science Immunology 3:aap8029. DOI: https://doi.org/10.1126/sciimmunol.aap8029, PMID: 29453292

Murugan R, Scally SW, Costa G, Mustafa G, Thai E, Decker T, Bosch A, Prieto K, Levashina EA, Julien JP, Wardemann H. 2020. Evolution of protective human antibodies against Plasmodium falciparum

Kucharska, Thai, et al. eLife 2020;9:e59018. DOI: https://doi.org/10.7554/eLife.59018

23 of 25
circumsporozoite protein repeat motifs. Nature Medicine 26:1135–1145. DOI: https://doi.org/10.1038/s41591-020-0881-9, PMID: 32451496
Nossé S. 1984. A unified formulation of the constant temperature molecular dynamics methods. The Journal of Chemical Physics 81:511–519. DOI: https://doi.org/10.1063/1.447334
Nussenzweig RS, Nussenzweig V. 1984. Development of sporozoite vaccines. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 307:117–128. DOI: https://doi.org/10.1098/rstb.1984.0113, PMID: 6084251
Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Liewens M, Kaslow DC, Njuguna P, Marsh K, Bejon P. 2016. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. New England Journal of Medicine 374:2519–2529. DOI: https://doi.org/10.1056/NEJMoai1515257
Oyen D, Torres JL, Wille-Reece U, Ockenhouse CF, Emerling D, Glanville J, Volkmuth W, Flores-García Y, Zavala F, Ward AB, King CR, Wilson IA. 2017. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. PNAS 114:E10438–E10445. DOI: https://doi.org/10.1073/pnas.1715812114, PMID: 29138320
Oyen D, Torres JL, Cottrell CA, Richter King C, Wilson IA, Ward AB. 2018. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Science Advances 4:eaau5529. DOI: https://doi.org/10.1126/sciadv.aau5529, PMID: 30324137
Parrinello M, Rahman A. 1981. Polymorphic transitions in single crystals: a new molecular dynamics method. Journal of Applied Physics 52:7182–7190. DOI: https://doi.org/10.1063/1.328693
Patra AP, Sharma S, Ainaravarapu SR. 2017. Force spectroscopy of the Plasmodium falciparum Vaccine Candidate Circumsporozoite Protein Suggests a Mechanically Pliable Repeat Region. Journal of Biological Chemistry 292:2110–2119. DOI: https://doi.org/10.1074/jbc.M116.754796, PMID: 28031457
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera—a visualization system for exploratory research and analysis. Journal of Computational Chemistry 25:1605–1612. DOI: https://doi.org/10.1002/jcc.20084, PMID: 15264254
Pholcharree T, Oyen D, Torres JL, Flores-García Y, Martin GM, González-Páez GE, Emerling D, Volkmuth W, Locke E, King CR, Zavala F, Ward AB, Wilson IA. 2020. Diverse antibody responses to conserved structural motifs in Plasmodium falciparum circumsporozoite protein. Journal of Molecular Biology 432:1048–1063. DOI: https://doi.org/10.1016/j.jmb.2019.12.029, PMID: 31883801
Plana S, Lindorff-Larsen K, Shaw DE. 2011. How robust are protein folding simulations with respect to force field parameterization? Biophysical Journal 100:L47–L49. DOI: https://doi.org/10.1016/j.bpj.2011.03.051, PMID: 21539772
Plassmeyer ML, Reiter K, Shimp RL, Kotova S, Smith PD, Hurt DE, House B, Zou X, Zhang Y, Hickman M, Uchime O, Herrera R, Nguyen V, Glen J, Lebowitz J, Jin AJ, Miller LH, MacDonald NJ, Wu Y, Narum DL. 2009. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. Journal of Biological Chemistry 284:26951–26963. DOI: https://doi.org/10.1074/jbc.M109.013706, PMID: 19633296
Portugal S, Tipton CM, Sohn H, Kone Y, Wang J, Li S, Skinner J, Vartaneva K, Sturdevant DE, Porcella SF, Doumbo OK, Doumbo S, Kayentao K, Ongoiba A, Traore B, Sanz I, Pierce SK, Crompton PD. 2015. Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. eLife 4:e07218. DOI: https://doi.org/10.7554/eLife.07218
Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. Journal of Experimental Medicine 151:1504–1513. DOI: https://doi.org/10.1088/jem.151.6.1504, PMID: 6991628
Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. 2017. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nature Methods 14:290–296. DOI: https://doi.org/10.1038/nmeth.4169, PMID: 28165473
Punjani A, Fleet DJ. 2020. 3d variability analysis: directly resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM images. bioRxiv. DOI: https://doi.org/10.1101/2020.04.08.032466
Rauscher S, Pomès R. 2012. Structural disorder and protein elasticity. Advances in Experimental Medicine and Biology 725:159–183. DOI: https://doi.org/10.1007/978-1-4614-0659-4_10, PMID: 22399324
Rauscher S, Pomès R. 2017. The liquid structure of elastin. eLife 6:e26526. DOI: https://doi.org/10.7554/eLife.26526, PMID: 29120326
Rich SM, Ferreira MU, Ayala FJ. 2000. The origin of antigenic diversity in Plasmodium falciparum. Parasitology Today 16:390–396. DOI: https://doi.org/10.1016/S0169-4758(00)01741-5, PMID: 10951599
Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK. 2001. Sequence complexity of disordered protein. Structures, Function, and Genetics 42:38–48. DOI: https://doi.org/10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3, PMID: 11093259
Rosenberg R, Wirtz RA, Schneider I, Burge R. 1990. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Transactions of the Royal Society of Tropical Medicine and Hygiene 84:209–212. DOI: https://doi.org/10.1016/S0335-9203(90)90258-G, PMID: 2202010
Ross LS, Fidock DA. 2019. Elucidating mechanisms of Drug-Resistant Plasmodium falciparum. Cell Host & Microbe 26:35–47. DOI: https://doi.org/10.1016/j.chom.2019.06.001, PMID: 31295423
Rouge L, Chiang N, Steffek M, Kugel C, Croll Tl, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C, Kraft E, Payandeh J, Nalimu G, Koerber JT, Rohou A. 2020. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367:1224–1230. DOI: https://doi.org/10.1126/science.aaz9556, PMID: 32079680
RTS,S Clinical Trials Partnership, Agnandji ST, Lelli B, Souloumoudjigar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methoho BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlar J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, et al. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in children in africa. The New England Journal of Medicine 365:1863–1875. DOI: https://doi.org/10.1056/NEJMoa1102287, PMID: 22007715

RTS,S Clinical Trials Partnership, Agnandji ST, Lelli B, Fernandes JF, Abossolo BP, Methoho BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlar J, Aide P, Lanaspa M, Aponte JJ, Macheco S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in african infants. The New England Journal of Medicine 367:2284–2295. DOI: https://doi.org/10.1056/NEJMoab1208394, PMID: 23136909

RTS,S Clinical Trials Partnership. 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in africa: final results of a phase 3, individually randomised, controlled trial. The Lancet 386:31–45. DOI: https://doi.org/10.1016/S0140-6736(15)60721-8, PMID: 25913272

Rubinstein JL, Brubaker MA. 2015. Alignment of cryo-EM movies of individual particles by optimization of image translations. Journal of Structural Biology 192:188–195. DOI: https://doi.org/10.1016/j.jsb.2015.08.007

Scally SW, Murugan R, Bosch A, Triller G, Costa G, Mordmüller B, Kremsner PG, Sim BKL, Hoffman SL, Levashina EA, Wardemann H, Julien JP. 2018. Rare PISCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. Journal of Experimental Medicine 215:63–75. DOI: https://doi.org/10.1084/jem.20170869, PMID: 29167197

Scally SW, Julien JP. 2018. Peek-Peak-Pique: repeating motifs of subtle variance are targets for potent malaria antibodies. Immunity 48:851–854. DOI: https://doi.org/10.1016/j.immuni.2018.04.037, PMID: 29768173

Schrödinger LLC. 2015. The PyMOL Molecular Graphics System.

Sherrard-Smith E, Sala KA, Betancourt M, Upton LM, Angrisano F, Morin MJ, Ghanì AC, Churcher TS, Blagborough AM. 2018. Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. eLife 7:e35213. DOI: https://doi.org/10.7554/eLife.35213, PMID: 29914622

Smith RC, Vega-Rodríguez J, Jacobs-Lorena M. 2014. The plasmodium bottleneck: malaria parasite losses in the mosquito vector. Memórias Do Instituto Oswaldo Cruz 109:644–661. DOI: https://doi.org/10.1590/0074-0276130597

Sullivan RT, Kim CC, Fontana MF, Feneey ME, Jagnannathan P, Boyle MJ, Drakeley CJ, Ssewanyana I, Nankya F, Mayanja-Kizza H, Dorsey G, Greenhouse B. 2015. FCRL5 delineates functionally impaired memory B cells associated with Plasmodium falciparum exposure. PLOS Pathogens 11:e1004894. DOI: https://doi.org/10.1371/journal.ppat.1004894, PMID: 25993340

Tahar R, Ringwald P, Basco LK. 1998. Heterogeneity in the circumsporozoite protein gene of plasmodium malariae isolates from sub-Saharan africa. Molecular and Biochemical Parasitology 92:71–78. DOI: https://doi.org/10.1016/s0078-6956(98)00022-6

Tan JC, Tan A, Checkley L, Honsa CM, Ferdig MT. 2010. Variable numbers of tandem repeats in Plasmodium falciparum genes. Journal of Molecular Evolution 71:268–278. DOI: https://doi.org/10.1007/s00239-010-9381-8, PMID: 20730584

Tan J, Sack BK, Oyen D, Zinkluesen I, Piccoli L, Barbieri S, Foglierini M, Fregni CS, Marcandalli J, Jongo S, Abdullah S, Perez L, Corradin G, Varani L, Sallusto F, Sim BKL, Hoffman SL, Kappe SHI, Daubenberger C, Wilson IA, et al. 2018. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nature Medicine 24:401–407. DOI: https://doi.org/10.1038/nm.4513, PMID: 29554084

Tivol WF, Briegel A, Jensen GJ. 2008. An improved cryogen for plunge freezing. Microscopy and Microanalysis 14:375–379. DOI: https://doi.org/10.1017/s1431927608080781, PMID: 18793481

Triller G, Scally SW, Costa G, Pissarev M, Kreschel C, Bosch A, Marois E, Sack BK, Murugan R, Salman AM, Janse CJ, Khan SM, Levashina EA, Wardemann H, Julien JP, Wardemann H. 2017. Natural parasite exposure induces protective human Anti-Malarial antibodies. Immunity 47:1197–1209. DOI: https://doi.org/10.1016/j.immuni.2017.11.007, PMID: 29195810

WHO. 2019. World Malaria Report 2018.

Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Akawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71–73. DOI: https://doi.org/10.1126/science.6985745, PMID: 6985745

Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. 1983. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. Journal of Experimental Medicine 157:1947–1957. DOI: https://doi.org/10.1084/jem.157.6.1947, PMID: 6189951